<DOC>
	<DOCNO>NCT01812954</DOCNO>
	<brief_summary>This study health economic analysis medicinal treatment option moderate-to-severe psoriasis vulgaris societal perspective . Efficacy data clinical outcome derive up-to-date meta-analysis randomize clinical trial ( RCTs ) moderate-to-severe psoriasis . Direct indirect cost extract various different source , include summary product characteristic ( SPCs ) German S3 guideline psoriasis care , health care utilization data official statistic . The study aim investigate comparative cost-effectiveness biologic conventional systemic treatment currently ( June 1st , 2012 ) approve moderate-to-severe plaque-type psoriasis Germany . Effectiveness measure mean pool ( Psoriasis Area Severity Index ) PASI-75 response rate report RCTs Direct cost well indirect cost consider .</brief_summary>
	<brief_title>Economic Evaluation Systemic Treatments Moderate-to-severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Acitretin</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>diagnosis moderatetosevere psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>moderate-to-severe psoriasis</keyword>
	<keyword>cost utility analysis</keyword>
	<keyword>cost effectiveness analysis</keyword>
	<keyword>systemic treatment</keyword>
</DOC>